Pfizer and BioNTech won a round in their legal battle with Moderna over COVID-19 vaccine patents on Wednesday, convincing a U ...

As part of a global web of patent litigation over COVID-19 vaccines and mRNA technology, Pfizer and its partner BioNTech ...

A German court found Wednesday that American pharmaceutical giant Pfizer and German firm BioNTech violated a patent to make ...

Children shouldn't receive the Moderna or Pfizer-BioNTech vaccines if they've had a severe allergic reaction to the ...

It's not the first time Pfizer and BioNTech have been accused of patent infringement with Comirnaty, as another mRNA COVID-19 vaccine developer – CureVac – filed a suit in Germany last month ...

In addition, Pfizer pays an attractive dividend, making the stock a favorite of income-seeking investors. This COVID-19 vaccine remains BioNTech's primary revenue source for now. However ...

The Pfizer/BioNTech bivalent COVID-19 vaccine (Original and Omicron BA.4/BA.5) has the FDA’s EUA for use in individuals 5 years and over as a single booster dose administered at least two months ...

BioNTech lowers full-year revenue outlook on COVID-19 seasonality, inventory write-downs November 4, 2024 Pfizer CEO Albert Bourla, under pressure from activist hedge fund Starboard Value ...

while antiviral treatment Paxlovid was $727 million for the quarter. Pfizer makes the Comirnaty vaccine with German partner BioNTech.

In multiple independent studies, significantly lower antibody levels and more vaccine breakthrough infections have been detected in the Pfizer/BioNTech-vaccinated population. These could be explained ...